America’s medical technology industry creates life-saving and life-enhancing treatments and cures that drive efficiencies and cost savings in the health care system, improve the quality of patient care, and generate high-quality jobs that contribute to economic growth. But today, the innovation ecosystem that supports medical technology development is severely stressed. The U.S. has historically been the world leader in medical technology, but our leadership is eroding. To respond to these challenges, AdvaMed has proposed a new Innovation Agenda.
While AZBio and its members recognize that the State of Arizona and the legislature must work diligently to balance the State Budget – which includes implementation of SB1475 and a 5% rate cut to providers of healthcare services – the end result may ultimately increase the state’s healthcare spend rather than reduce it.Continue reading
The success of the Jumpstart Our Business Startups (JOBS) Act in the biotech industry means that the work of the Subcommittee on Capital Markets and Government Sponsored Enterprises has taken on increased importance for emerging biotech companies. Current bills being considered could help to further support the search for breakthrough treatments at the next generation of emerging growth biotech companies.Continue reading
Representative Eric Meyer serves as House Minority Leader in the Arizona House of Representatives.
In the wee hours of Saturday morning, the Arizona Legislature approved a new budget. The Governor lauded it as fiscally responsible, but is it strategically wise as we look at what it means to Arizona today and in the future? Continue reading
If we want to be globally competitive, we need to commit to the resources it takes to compete. As Arizonans, now is our opportunity to let our elected leaders know how important we believe this is for our state today and tomorrow.Continue reading
This Washington Update for CSBA is provided to AZBio Members as an update on issues that affect our industry at the nation’s capitol.Continue reading
Washington, DC (March 5, 2014) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement in response to President Obama’s FY 2015 budget proposal:Continue reading
Results Show Substantial Job Loss, Reduction in R&DContinue reading